Core Viewpoint - BioNTech has successfully completed the initial offering period for the acquisition of CureVac, with approximately 81.74% of CureVac's shares tendered, allowing the company to proceed with the transaction and subsequent reorganization [1][8]. Group 1: Acquisition Details - A total of 184,071,410 shares of CureVac were validly tendered, satisfying the minimum condition for the exchange offer [1][8]. - The subsequent offering period for CureVac shareholders who have not yet tendered their shares will expire at 12:01 a.m. Eastern Time on December 18, 2025 [2][8]. - Following the expiration of the subsequent offering period, non-tendering holders of CureVac shares will receive BioNTech American Depositary Shares (ADSs) or cash in lieu of fractional ADSs as part of the post-offer reorganization [3]. Group 2: Tax Implications and Trading Status - Non-tendering holders of CureVac shares will generally be subject to a 15% Dutch dividend withholding tax when receiving BioNTech ADSs [3]. - Shares held by non-tendering CureVac shareholders will cease to be tradable on any national stock exchange after the completion of the post-offer reorganization [4]. Group 3: Company Background - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and other serious diseases, utilizing a diverse portfolio that includes mRNA cancer immunotherapies and targeted therapies [5]. - The company has established collaborations with various global pharmaceutical partners, enhancing its research and development capabilities [5].